Nirvana Life Sciences Inc. Announces Receipt of First North American Production of SOSA, a Patented, WHO Approved, Herbal Treatment for Opiate Addiction
Vancouver, British Columbia--(Newsfile Corp. - January 29, 2024) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a western Canadian-based life sciences company, is pleased to report that it has received its first shipment of "SOSA", a leading addictions focused herbal treatment.SOSA is a patented, WHO-approved, herbal treatment for opiate addiction that has been administered to more than 30 million patients in Asia. SOSA is registered with the health authorities in China,...
2024-01-29 9:01 AM EST
Nirvana Life Sciences Inc. Announces Acquisition of Licensed Distributor of a Patented, WHO Approved, Herbal Treatment for Opiate Addiction
Vancouver, British Columbia--(Newsfile Corp. - August 15, 2023) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the " Company"), a western Canadian based life sciences company aimed at developing psychedelic and other natural based medicines, including non-addictive chronic pain and relapse preventing pharmaceutical medicines, is pleased to report that it has completed its acquisition of Medsmart Dispensary Inc, the distributor of a leading addictions focused herbal treatment.Nirvana...
2023-08-15 10:53 AM EDT
Nirvana Life Sciences Inc. Announces the Acquisition of Licensed Distributor of a Patented, WHO Approved, Herbal Treatment for Opiate Addiction
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2023) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a western Canadian based life sciences company aimed at developing psychedelic and other natural based medicines, including non-addictive chronic pain and relapse preventing pharmaceutical medicines, is pleased to report that it has entered into a definitive agreement for the acquisition of Medsmart Dispensary Inc., the distributor of a leading addictions focused...
2023-06-07 9:14 AM EDT
Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2022) - Nirvana Life Sciences Inc.(CSE: NIRV) (Nirvana or the "Company") , a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Sheldon Inwentash to the Company's Board of Directors.Mr. Inwentash is founder, chairman and chief executive officer of ThreeD Capital Inc. A veteran entrepreneur, Sheldon has more than 30 years of...
2022-11-09 8:57 AM EST
Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian-based life sciences company focused on developing novel therapeutic products derived from psychedelics to produce non-addictive solutions for opioid addiction treatment and ongoing pain management, in conjunction with Integrative Therapy Discovery (ITD) Labs in Italy, have released comprehensive data on a scientific study that aims in determining the...
2022-06-02 1:00 PM EDT
ThreeD Capital Increases Its Investment in Nirvana
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) ("Nirvana" or the "Company") is pleased to announce that ThreeD Capital Inc. has increased its investment in Nirvana. The Company announces that it has completed a non-brokered private placement of 500,000 units at a price of $0.30 per unit, for net proceeds of $150,000.00. Each unit consists of one share and one warrant to purchase a share at a price of $0.50 per share with...
2022-05-31 7:43 PM EDT
Nirvana Life Sciences Announces Partner Symeres Can Produce High Volume Controlled Substances
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a western Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products announces that its strategic partners Symeres are licensed to produce large quantities of controlled compounds required by Nirvana.The company is excited to announce that strategic partner Symeres has confirmed with Nirvana Life Sciences,...
2022-05-24 7:32 AM EDT
Nirvana Signs Letter of Intent with Innovate Phytotechnologies Inc.
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products, is pleased to announce that it has signed a letter of intent with Innovate Phytotechnologies Inc. (INVP) for the development and distribution of the Company's psilocybin and psilocin based products. The strategic relationship will begin with the...
2022-05-17 9:00 AM EDT
Nirvana Life Sciences Inc. Announces the Appointment of Jakson Inwentash to the Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - May 3, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Jakson Inwentash to the Company's Board of Directors.Mr. Inwentash is a Director and VP Investments at ThreeD Capital, where he focuses on identifying, researching, and meeting with early-stage companies...
2022-05-03 9:00 AM EDT
Nirvana Reports Progress with Health Canada Dealer's License Application and Facility Development
Vancouver, British Columbia--(Newsfile Corp. - April 26, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce an update on licensing and development for its Vancouver Lab facility.Mr. Michael McCune, Vice President Operations commented, "We are pleased with the steady progress that our team is making on licensing. The application...
2022-04-26 8:49 AM EDT
Nirvana Announces First Production of Psilocybin and Psilocin
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) ("Nirvana" or the "Company") is pleased to announce that its supply agreement with Symeres B.V. has produced its first 20 grams of Psilocybin and 20 grams of Psilocin. These materials will support the Company's ongoing research and development projects.Dr. Sazzad Hossain, Chief Scientific Officer of Nirvana commented, "We are very pleased to have these materials available as we enter the...
2022-04-21 9:00 AM EDT
Nirvana Life Sciences Inc. Contracts Stratus Designs for Mechanical Service to Laboratory
Vancouver, British Columbia--(Newsfile Corp. - April 12, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce that it has engaged Stratus Designs Ltd. to undertake design of mechanical and control systems for its Vancouver Lab facility.Adam Clarke, CEO and Principal Consultant of Stratus commented, "The projects that Nirvana Life...
2022-04-12 9:00 AM EDT
Nirvana Reports Progress with Health Canada Dealer's License Application and Facility Development
Vancouver, British Columbia--(Newsfile Corp. - March 21, 2022) - Nirvana Life Sciences Inc., (CSE: NIRV) a Canadian based life sciences company aimed at developing non-addictive chronic pain and addiction treatment products is pleased to announce progress with licensing and development of its Vancouver research and development facility.The Company applied for a Dealer's License from Health Canada in July of 2021. That application is currently in the final review stage, with approval expected...
2022-03-21 2:07 PM EDT
Endocan Announces Closing of Financing
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2021) - Endocan Solutions Inc. ("Endocan" or the "Company") announces that it has completed a non-brokered private placement of 1,914,529 shares at a price of $0.35 per share for net proceeds of $670,085.00. The Company will use the net proceeds from the Financing to fund operations. The Shares issued will be subject to a statutory four month hold period. About Endocan Solutions Inc.Endocan Solutions Inc. is a Reporting Issuer that...
2021-09-23 4:08 PM EDT
Endocan Announces Amendment to Agreement to Acquire Nirvana Life Sciences Inc.
Vancouver, British Columbia--(Newsfile Corp. - August 16, 2021) - Endocan Solutions Inc. ("Endocan" or the "Company") is pleased to announce that it has executed an amendment (the "Amendment") to the share exchange agreement dated June 4, 2021 among Endocan, Nirvana Life Sciences Inc. ("Nirvana") and the shareholders of Nirvana.The Amendment reflects the fact that Endocan will be acquiring 39,455,095 Nirvana shares (which constitutes 99.06% of the issued and outstanding shares of Nirvana)...
2021-08-16 8:06 PM EDT
Endocan Announces Agreement to Acquire Nirvana Life Sciences Inc. and Financing
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2021) - Endocan Solutions Inc. ("Endocan" or the "Company") announces the signing of a share exchange agreement (the "Agreement") for the acquisition of Nirvana Life Sciences Inc. ("Nirvana"). The acquisition will result in the Company acquiring 100% of the issued and outstanding common shares of Nirvana by way of Reverse Take-Over or Change of Business (the "Transaction"). The Company will issue approximately 39,000,000 common shares...
2021-06-04 6:06 PM EDT
Revocation of Cease Trade Orders Granted and Company Announces Date for Annual and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2019) - Endocan Solutions Inc. (the "Company" or "Endocan") reports that the cease trade order issued by the British Columbia Securities Commission (BCSC) on May 3, 2016 and the cease trade order issued by the Ontario Securities Commission (OSC) on May 6, 2016 have been revoked. The Company has set December 20, 2019 for its Annual General & Special Meeting of Shareholders.The Company is currently pursuing a business acquisition and is...
2019-10-21 3:58 PM EDT
Endocan Files Amended MD&A and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2019) - Endocan Solutions Inc. (the "Company" or "Endocan") Endocan announces that, as a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure.In February 2019 the Company signed a non-binding letter of intent ("LOI") with Hai Beverages Inc. for the Company to purchase all of the issued and outstanding voting shares in Monashee Medicinal MJ from Hai...
2019-10-09 5:51 PM EDT
Endocan Solutions Receives Notice of Claim
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2019) - Endocan Solutions Inc. (CSE: WWM-Delisted) (the "Company" or "Endocan") announces that it has received a notice of claim filed in the Supreme Court of British Columbia by Agilis Capital Corporation and Robert Van Santen (the "Plaintiffs") alleging that the Plaintiffs are collectively owed $301,882 for outstanding consulting fees, severance compensation and GST together with special damages in respect to an executive services...
2019-09-23 6:22 PM EDT
Endocan Solutions Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2019) - Endocan Solutions Inc. (CSE: WWM) (Delisted) (the "Company" or "Endocan") announces that Robert Marsh and Robert van Santen have resigned as directors of the Company. The Company thanks them for their service on the Board and wishes them well in their future endeavours. About Endocan Solutions Inc. Endocan Solutions Inc. is a Reporting Issuer undergoing recapitalization and reorganization. It was delisted from the CSE on...
2019-09-10 1:06 PM EDT